Neoadjuvant T-VEC Improves Survival in Resectable Melanoma

Source: Cancer Therapy Advisor, October 2021

Neoadjuvant talimogene laherparepvec (T-VEC) followed by surgery significantly improved survival, when compared with surgery alone, in patients with advanced, resectable melanoma, according to research published in Nature Medicine.

READ THE ORIGINAL FULL ARTICLE
Menu